Exagen Inc Total Assets
Exagen Inc total assets. Based on the latest financial reports, Exagen Inc (XGN) holds total assets worth $51.94 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see XGN company net worth for the company's overall valuation and market capitalisation.
Total Assets of Exagen Inc (2012–2025)
Total assets of Exagen Inc from 2012 to 2025. This chart illustrates how Exagen Inc's total assets have evolved over time, based on quarterly financial data. See Exagen Inc share price for real-time trading data and today's change.
Exagen Inc - Asset Composition Analysis
Exagen Inc Total Assets Breakdown (December 2025)
Exagen Inc total assets breakdown as of December 2025. Exagen Inc's total assets of $51.94 Million consist of 84.3% current assets and 15.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 55.5% |
| Accounts Receivable | $10.86 Million | 18.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Exagen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore XGN net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Exagen Inc's current assets represent 84.3% of total assets in 2025, an increase from 31.7% in 2012.
- Cash Position: Cash and equivalents constituted 55.5% of total assets in 2025, up from 24.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 59.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 18.7% of total assets.
Exagen Inc Competitors by Total Assets
Key competitors of Exagen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
India | Rs15.07 Billion |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €18.96 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
Exagen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.18 | 4.95 | 14.62 |
| Quick Ratio | 3.18 | 4.95 | 14.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $29.40 Million | $40.69 Million | $110.28 Million |
Exagen Inc - Advanced Valuation Insights
This section examines the relationship between Exagen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.48 |
| Latest Market Cap to Assets Ratio | 3.05 |
| Asset Growth Rate (YoY) | 29.8% |
| Total Assets | $58.02 Million |
| Market Capitalization | $177.09 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Exagen Inc's assets at a significant premium (3.05x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Exagen Inc's assets grew by 29.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Exagen Inc (2012–2025)
The table below shows the annual total assets of Exagen Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $58.02 Million | +29.84% |
| 2024-12-31 | $44.69 Million | -21.52% |
| 2023-12-31 | $56.94 Million | -33.96% |
| 2022-12-31 | $86.22 Million | -30.15% |
| 2021-12-31 | $123.44 Million | +57.51% |
| 2020-12-31 | $78.38 Million | -11.25% |
| 2019-12-31 | $88.31 Million | +205.71% |
| 2018-12-31 | $28.89 Million | +41.67% |
| 2017-12-31 | $20.39 Million | +39.40% |
| 2015-12-31 | $14.63 Million | -14.71% |
| 2014-12-31 | $17.15 Million | +4.24% |
| 2013-12-31 | $16.45 Million | +46.02% |
| 2012-12-31 | $11.27 Million | -- |
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead test… Read more